Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the glaucoma market grown over the years?

The size of the glaucoma market has experienced robust growth in the past few years. The market, which is projected to be worth $7.76 billion in 2024, is forecasted to increase to $8.22 billion in 2025 with a compound annual growth rate (CAGR) of 5.9%. Several factors have contributed to this increase during the historical period, including increased awareness about eye health, higher healthcare expenditure, the rising utilization of telemedicine for eye care, a growing healthcare infrastructure, and increased government initiatives in healthcare.

What Is the forecasted market size and growth rate for the glaucoma market?

The market size for glaucoma is projected to experience robust expansion in the incoming years, with an anticipated worth of $10.20 billion in 2029, and a compound annual growth rate (CAGR) of 5.5%. The projected growth during this period can be linked to factors such as an aging population, increased incidence of glaucoma, a surge in demand for less invasive surgeries, increasing diabetes cases, and heightened hypertension prevalence. Noteworthy trends for this forecast period encompass improvements in diagnostic technologies, the introduction of new medicinal treatments, technological advancements in surgical equipment, the presence of combined therapies, and the implementation of robotic surgeries.

Get your glaucoma market report here!

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

What are the major factors driving growth in the glaucoma market?

The growth of the glaucoma market is anticipated to be driven by the increasing incidence of chronic eye conditions. Such conditions are long-term ailments that affect the eyes, often leading to perpetual visual impairment or discomfort and necessitating consistent treatment or management. The rising number of chronic eye conditions can be attributed to aging populations, increased screen exposure, lifestyle factors, and a rise in conditions like diabetes and hypertension. To prevent further damage to the optic nerve, preserve vision, and lower intraocular pressure, glaucoma treatment is necessary since untreated glaucoma can result in irreversible blindness. For example, as reported by the National Health Service (NHS) in the UK in December 2024, over 2 million people in the UK were experiencing sight loss in 2024. Moreover, the population suffering from sight loss is predicted to grow by 27%, amounting to nearly 2.8 million by 2035. Thus, the escalation in chronic eye conditions is propelling the glaucoma market.

What key areas define the segmentation of the global glaucoma Market?

The glaucoma market covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types

2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy

3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes

4) By Administration: Oral, Injections, Intravitreal, Other Administrations

5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp

What are the top market players propelling the growth of the glaucoma industry?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG

What are the key trends shaping the future of the glaucoma market?

Major companies operating in the glaucoma market are focusing on developing innovative therapies, such as Rho-kinase (ROCK) inhibitors, to offer a dual mechanism of action, reducing intraocular pressure through both enhanced outflow of aqueous humor and the relaxation of trabecular meshwork cells, making them effective in treating glaucoma. Rho-kinase (ROCK) inhibitors are a class of drugs that target and block the activity of Rho-kinase enzymes, which regulate cell contraction and treat glaucoma to reduce intraocular pressure. For instance, in July 2023, Santen Pharmaceutical Co. Ltd., a Japan-based eye care products company, launched Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, that effectively reduces intraocular pressure (IOP) by targeting trabecular meshwork dysfunction. It is indicated for adult patients with primary open-angle glaucoma or ocular hypertension who have not achieved adequate IOP reduction with monotherapy using a prostaglandin or netarsudil. The introduction of Roclanda in Europe marks the first new class of glaucoma medication in 25 years, offering a breakthrough in treatment. By combining netarsudil and latanoprost, Roclanda works synergistically to increase outflow through trabecular (conventional) and uveoscleral (unconventional) pathways, providing a comprehensive approach to managing elevated IOP.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820

What regions are dominating the glaucoma market growth?

North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Antiglaucoma Drugs Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/antiglaucoma-drugs-market

Antiglaucoma Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Glaucoma Surgery Devices Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/glaucoma-surgery-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: